| Literature DB >> 15572 |
S Habersang, F Leuschner, F Stroman, A Domenico, A Schlichtegroll.
Abstract
1. 7-(3-[2-(3,5-Dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, D 1959, Bronchospasmin) was developed as a bronchospasmolytic agent from the structure class of the phenylethyl-aminoalkyl-xanthines. 2. The pharmacological effects characterize reproterol as a bronchospasmolytic with preferential impact on the adrenergic beta2-receptors. 3. In the therapeutic dose range, reproterol stands out because of its nearly non-existent cardiovascular or central nervous side effects. Effects of over and above pharmacodynamically effective doses as well as toxic ones may be reversed with beta1-receptor blockers.Entities:
Mesh:
Substances:
Year: 1977 PMID: 15572
Source DB: PubMed Journal: Arzneimittelforschung ISSN: 0004-4172